Member Info for miti1000

I think the really big news, apart from the Nasdaq IPO, is going to be the Savolitinib results in January. Real chance of being fast tracked if they are good.

Yes, I suppose I am biased having bought in heavily recently so could do without a delay in floating on Nasdaq. The IPO window has closed a bit in the US but not for quality propositions. Tbh, I feel it would be a big mistake to miss this window .With so much big news in the next year,HCM really need to get exposure to US investors and raise money( way more than $100million ) and increase their profile with the FDA as they have intimated they would like to do. They will need that money as well as Phase3 trails are most cost intensive. Sometimes you get just one chance and then the opportunity is lost. So lets hope they grasp their chance and got for it now.

Does the price action say to you that they will delay the IPO ? It doesn't to me.

Hutchison China Meditech (LON:HCM) – Buy Yesterday, Hutchison China Meditech (Chi-Med) informed that its joint venture (JV) Shanghai Hutchison Pharmaceuticals Limited (SHPL) has agreed to surrender its remaining 36 years of land-use rights on an old factory site in Shanghai. The site is located at around 12 km from the city, which was rezoned in 2014 from industrial use into a new science and technology, commercial and residential development area called Smart City. SHPL plans to build the new factory in Fengpu district, which is located 40 km south of Shanghai city centre. The cost of new factory is around US$100m, with 80% of it already incurred and funded through cash reserves and bank borrowings of US$38m as at 30th November 2015. SHPL would receive compensation of US$105m from the acquirers. As per the agreement, the amount would be paid in three stages over a span of one year. Our view: This is positive news for Chi-Med as its partners SHPL plan to start a new factory at Fengpu with modern facilities and enhanced efficiencies. Additionally, the company plan to use the funds to pay off debt, distribute dividends to shareholders of SHPL and finance working capital needs. Earlier this week, Hutchison MediPharma Limited (HMP), Chi-Med’s drug R&D subsidiary initiated FALUCA, a Phase III registration study for fruquintinib (HMPL‑013) in third-line non-squamous non-small cell lung cancer (NSCLC) patients in China. Recently, HMP started the Phase I clinical trial of sulfatinib (HMPL-012) in the United States. In addition, the first in-human Phase I clinical trials on HMPL-523 have been positive and in line with its expectations. The drug is useful in various immune system associated diseases, such as autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus and allergy, as well as haematological cancers including lymphoma and leukaemia. Furthermore, HMP is all set to receive a US$10m payment in Q4 2015 from its partner Eli Lilly. Going forward, HMP plans to start Phase III registration study for the treatment of neuroendocrine tumours and Phase Ib study for the treatment of thyroid cancer by the end of 2015. In light of the overall developments surrounding Chi-Med, we maintain a Buy rating on the stock.

All good news and everything on schedule it seems . Looks like we will have the Nasdaq float in January judging by the lack of news. US biotech investors will absolutely love HCM and I expect them to be clambouring for what is a tightly held stock.

Keep an eye out for the Beigene IPO on Nasdaq. Its much lower in quality than HCM imo but it will be interesting to guage investor reaction to it.Its also looking to raise $100million.

An interesting Bloomberg article ....from June 2015. http://www.bloomberg.com/news/articles/2015-06-18/chi-med-arthritis-drug-spurs-interest-from-potential-partners

Yes I'm very confident , Matt . A contest ?...you'd lose. As for your ''not without risk ' comment..sounds like the type of drivel to be uttered by a run of the mill equity portfolio manager. What investment is ' not without risk' ?? Perhaps, my comment was over the top but I don't like inane comments . Each to his own.

Matt, Well done on your £3 average and you;ve also made a fantastic call. As for you knowing more, very very unlikely. Good Luck anyhow.

Well, you have done great to have found this gem and moreover to have stuck with them. My average is around 25 quid and I have bought a lot of them. Lets see how it plays out.

Added another 2k at the same price.

Totally agree, davey . Feelslike this is the calm before the storm as news approaches. Its well offered at the moment .Have just bought another 1500 at 25.58 , although trade not showing up yet. Being so illiquid , it just takes one seller in the market to keep a lid on the price but that will all change as we move closer to the nasdaq listing and news.

whoops, that should 38 quid not 28quid!!

I think there will be quite a lot of churn as the increased volume allows those sellers to offload. I don;t tend to read too much into it. Having traded the markets for the past 15 years , and seen around 6 Uk to US flotations(eg. Sola, KFX, VEL etc) I've seen it all before. In reality , I believe that HCM is the highest quality company to make that particular move . Experience has shown , even in the absence of big news , that the share price appreciation either by the time of IPO or 3 months after is the range of 50% up. That would take us to around 28quid. That would be a minimum target for me but I think the upside will be much greater over the next 9 months.

An associate of mine attended the meeting today (as I could not attend) which was very sparsely attended. He spoke to both Simon To and Mr.Hogg. Both were very unbeat and everything is on course. Strong newsflow ahead. There were no hiccups. Professional courtesy prevents me from divulging anymore but needless to say, I will continue to add.

Unfortunately, I can;t make the meeting but if any one is going , I'd suggest you wait till the meeting finishes and try corner Mr. Hogg to ask a few questions. Directors are more open when you get a quiet word alone with them in my experience. I think the most pertinent would be what he considers the market cap of HCM to be when it lists on Nasdaq at this stage of its cycle and to what US listed companies , he compares to arrives at this valuation. A further question would be the timetable for the Nasdaq float. Are we talking about pre xmas as suggested by Investors Chronical or imo, a float in Jan/Feb . If you are able to get a word with one of the brokers ,Deutsche Bank or Merrill Lynch , that would probably be excellent to guage what demand they are seeing and an idea of price. They could well be in present. If anyone could keep us informed, that would be very helpful.

Matt, Nonsense , you clearly have not researched Nasdaq biotechs wrt valuations. By the time HCM Ipo' s on Nasdaq , you will see the share price closer to 40 than 30 quid imo.

That's a good purchase price. I'm waiting for some decent seller to pick up stock.. At the moment, you have pay a 10% spread just to get involved which is a joke. Good for holders though!! Good Luck.

Its not listed on AIm. Never the less , its a very hard stcok to buy. The mm's apear very short of stock. Just bought 4500 and had to pay 217. Looks a very interesting company. I shall be buying plenty despite its strong rise since IPO.

dalooks, best you stick to the tea leaves mate. You called this up 10% and its down almost 20%. One of the most embarrassing calls I've seen ....ever.